key: cord-0839095-6om47ho0
authors: Scicali, Roberto; Di Pino, Antonino; Piro, Salvatore; Rabuazzo, Agata Maria; Purrello, Francesco
title: May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?
date: 2020-05-13
journal: Nutr Metab Cardiovasc Dis
DOI: 10.1016/j.numecd.2020.05.003
sha: 5c8aed488324b5403283305936595e0423a70e18
doc_id: 839095
cord_uid: 6om47ho0

nan

Dear Editor, early data from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic disease causing 2019 coronavirus disease showed that the affected subjects were typically men aged by 40-60 years with several comorbidities; in particular, 25% of subjects with COVID-19 treated in an intensive care unit (ICU) had a history of cardiovascular diseases [1] . In this context, young subjects at increased risk of cardiovascular events such as familial hypercholesterolemia (FH) subjects may have deleterious consequences by COVID-19 [2] . Of note, COVID-19 may induce lipid abnormalities as previously described during Severe acute respiratory syndrome-coronavirus (SARS-CoV) infection [3] ; thus, the increased cumulative cholesterol burden may further exacerbate the cardiovascular risk of FH subjects. In this context, the adherence and intensification of lipid lowering therapies is necessary to adequately reduce cardiovascular risk in hypercholesterolemic subjects.

Another aspect to take into consideration is the role of cholesterol during viral infection especially in RNA virus; in fact, it is note that lipids and cholesterol-rich membrane microdomains are essential for flavivirus and coronavirus entries in human cell [4] . Of note, Glende et al. showed that cholesterol-rich membrane microdomains facilitated the interaction between the surface glycoprotein S of SARS-CoV and the cellular receptor angiotensin-converting enzyme 2 (ACE2) [5] . Moreover, after cellular entry, RNA virus require a high amount of intracellular cholesterol and fatty acids for the formation of the replication complex; in particular, Soto-Acosta et al. showed a high amount of cellular cholesterol correlated with an increased activity of the 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) during a RNA virus infection (HMGCR) [6] . In this context, lipid-lowering therapies may have a double benefical effect in hypercholesterolemic subjects by reducing the cardiovascular risk and interfering with COVID-19.

It's note that statin is the first lipid lowering choice in clinical practice and acts by inhibiting HMGCR.

Interestingly, Panes et al. have previously found that membrane cholesterol is increased in hypercholesterolemic than normo-cholesterolemic subjects; moreover, they showed that rosuvastatin effectively reduced membrane cholesterol levels in hypercholesterolemic subjects [7] . In this context, it may be interesting to evaluate the impact of high intensity statins (especially hydrophilic statins) in hypercholesterolemic subjects with COVID-19 in terms of morbidity and prognosis.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are the most recent available lipid lowering therapies able to halve low-density lipoprotein (LDL) cholesterol and significantly reduce the cardiovascular risk in hypercholesterolemic subjects such as FH [8] . PCSK9 inhibitors specifically bind and inhibit the circulating protein PCSK9; thus, PCSK9 inhibitors block LDL receptor (LDLR) degradation by PCSK9 and enhance LDLR expression on the hepatocyte surface. Concerning the impact of PCSK9 levels on viral infection, it was shown that PCSK9 promoted the degradation of LDLR-related protein 1 (LRP1) [9] . Of note, Gudleski-O'Regan et al. demonstrated that an increased LRP1 expression was associated with a reduced Cytomegalovirus (CMV) infectivity by depleting intracellular cholesterol in CMV-infected fibroblasts; thus, a higher LRP1 expression may be a defense response to virus infection [10] . In opposite, by inducing LRP1 degradation, PCSK9 may increase the viral infectivity and its inhibition may be useful to interfere with the infectivity of several virus such as COVID-19. In line with these considerations, PCSK9 inhibition was not associated with an increased risk of virus infection in clinical trials. It may be interesting to evaluate the impact of PCSK9-inhibitors on morbidity and prognosis of hypercholesterolemic subjects infected by COVID-19 .

In conclusion, hypercholesterolemic subjects such as FH have an increased risk of cardiovascular disease and their risk may be worsened by COVID-19; moreover, statins and PCSK9 inhibitors may be useful to reduce the cardiovascular risk and interfere with COVID-19 in FH subjects; further studies are needed to evaluate the impact of these lipid lowering therapies in hypercholesterolemic subjects infected by COVID-19.

The authors have no conflicts of interest to disclose.

Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Familial hypercholesterolemia and COVID-19: triggering of increased sustained cardiovascular risk

Altered Lipid Metabolism in Recovered SARS Patients Twelve Years after Infection

Rewiring cellular networks by members of the Flaviviridae family

Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavirus with the cellular receptor angiotensin-converting enzyme 2

The increase in cholesterol levels at early stages after dengue virus infection correlates with an augment in LDL particle uptake and HMG-CoA reductase activity

Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin

Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: A Two-Lipid Center Real-World Experience

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)

Increased expression of LDL receptor-related protein 1 during human cytomegalovirus infection reduces virion cholesterol and infectivity